SCHEMBL4155464

SCHEMBL4155464

FC(F)(F)c1ccc(-c2cc3c4ccccc4ccc3n2-c2ccccc2)cc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MGAM O43451 1/20 0.42
GAA P10253 1/20 0.42
SI P14410 1/20 0.42
MGAM2 Q2M2H8 1/20 0.42
ALOX5 P09917 1/20 0.40
PTGS2 P35354 1/20 0.40
KIF11 P52732 1/20 0.40
MAT2A P31153 1/20 0.39
GLO1 Q04760 1/20 0.39
PPARG P37231 2/20 0.38
PPARA Q07869 2/20 0.38
TDP2 O95551 1/20 0.37
KDM4E B2RXH2 1/20 0.37
ATM Q13315 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
CNR2 P34972 1/20 0.36
PDPK1 O15530 1/20 0.36
TEAD1 P28347 1/20 0.36
TEAD4 Q15561 1/20 0.36
TEAD2 Q15562 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4149264 0.90 KDM4E (0.37) MGAMGAASIMGAM2MAT2A
SCHEMBL2986715 0.87 PTGER1 (0.44) GAAPPARGPPARAKDM4EL3MBTL1
SCHEMBL2984870 0.82 CYP1A2 (0.50) PPARGPPARACNR2PDPK1
SCHEMBL4140780 0.82 ALDH1A1 (0.43) MAT2AKDM4EATML3MBTL1
SCHEMBL12091770 0.79 PTGER4 (0.45) KDM4EL3MBTL1
SCHEMBL3000516 0.79 KDM4E (0.39) GLO1PPARGPPARAKDM4EL3MBTL1
SCHEMBL4148027 0.78 DHODH (0.41) MAT2AKDM4EATML3MBTL1
SCHEMBL4148824 0.77 EGFR (0.46) MGAMKDM4EATML3MBTL1
SCHEMBL2991546 0.77 PLA2G10 (0.43) GAAPPARGPPARAKDM4EL3MBTL1
SCHEMBL2986744 0.77 KMT2A (0.49) PPARGPPARAKDM4ECNR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9216966-B2 Compounds for Alzheimer's disease Manfredi, John (US) 2015-12-22 US disclosed
US-9034871-B2 Compounds for Alzheimer's disease Manfredi, John (US) 2015-05-19 US disclosed
EP-1809601-B1 COMPOUNDS FOR ALZHEIMER'S DISEASE MANFREDI JOHN (US) 2014-09-10 EP disclosed
US-20130261118-A1 COMPOUNDS FOR ALZHEIMER'S DISEASE MANFREDI JOHN (US) 2013-10-03 US disclosed
US-20120225873-A1 COMPOUNDS FOR ALZHEIMER'S DISEASE MYREXIS, INC. (US) 2012-09-06 US disclosed
US-20090099179-A1 COMPOUNDS FOR DISEASES AND DISORDERS MYRIAD GENETICS, INCORPORATED (US) 2009-04-16 US disclosed
US-20080249135-A1 N-phenylindoles; oral dosage forms; side effect reduction MYRIAD GENETICS, INCORPORATED (US) 2008-10-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130261118-A1 COMPOUNDS FOR ALZHEIMER'S DISEASE SLC18A2, SLC18A3, NLN MGAM 3609/4885GAA 526/4885SI 3884/4885
US-20090099179-A1 COMPOUNDS FOR DISEASES AND DISORDERS CLN6, NLN, CLTC MGAM 4438/4885GAA 401/4885SI 4442/4885
US-20080249135-A1 N-phenylindoles; oral dosage forms; side effect reduction NCL, PSEN2, CCNO MGAM 3864/4885GAA 1170/4885SI 1179/4885
US-20120225873-A1 COMPOUNDS FOR ALZHEIMER'S DISEASE PSEN2, CHAT, PSEN1 MGAM 4107/4885GAA 975/4885SI 3589/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.